As of June 30, 2024, VYNE had cash, cash equivalents, restricted cash and marketable securities of $78.1 million. VYNE believes its cash, cash equivalents, restricted cash and marketable securities as of June 30, 2024 will be sufficient to fund its operations through the end of 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
- VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Vyne Therapeutics Inc (VYNE) Q2 Earnings Cheat Sheet
- VYNE Therapeutics announces granting of composition of matter patent for VYN202
- VYNE Therapeutics announces appointment of Banerjee as SVP
- VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum